Local Delivery of Cannabinoid-Loaded Microparticles Inhibits Tumor Growth in a Murine Xenograft Model of Glioblastoma Multiforme

PLoS ONE

Volumn 8, Issue 1, 2013, Pages

  Hernán Pérez de la Ossa, Dolores ^a   Lorente, Mar ^a,b   Gil Alegre, Maria Esther ^a   Torres, Sofía ^a   García Taboada, Elena ^a   Aberturas, María del Rosario ^c   Molpeceres, Jesús ^c   Velasco, Guillermo ^a,b   Torres Suárez, Ana Isabel ^a  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^b HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^c UNIVERSITY OF ALCALÁ   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CANNABIDIOL; POLYCAPROLACTONE; TETRAHYDROCANNABINOL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CELL PROLIFERATION; CONCENTRATION RESPONSE; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG SCREENING; GLIOBLASTOMA; HUMAN; HUMAN CELL; IN VITRO STUDY; MICROENCAPSULATION; MOUSE; NONHUMAN; PARTICLE SIZE; SUSTAINED DRUG RELEASE; TIMED DRUG RELEASE; TREATMENT DURATION; TUMOR VASCULARIZATION; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CANNABIDIOL; CANNABIS; CELL PROLIFERATION; DRUG DELIVERY SYSTEMS; GLIOBLASTOMA; HUMANS; MICE; POLYMERS; TETRAHYDROCANNABINOL; TRANSPLANTATION, HETEROLOGOUS;

ANIMALIA; CANNABIS; CANNABIS SATIVA; MURINAE; MUS;

EID: 84872912661     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0054795     Document Type: Article

References (41)

1. Gaoni Y, Mechoulam R, (1964) Isolation, structure and partial synthesis of an active constituent of hashish. J Am Chem Soc 86: 1646-1647.
2. Howlett AC, Barth F, Bonner TI, Cabral G, Casellas P, et al. (2002) International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol Rev 54: 161-202.
3. Fernandez-Ruiz J, Romero J, Velasco G, Tolon R, Ramos J, et al. (2007) Cannabinoid CB2 receptor: a new target for controlling neural cell survival? Trends Pharmacol Sci 28: 39-45.
4. Di Marzo V, (2009) The endocannabinoid system: its general strategy of action, tools for its pharmacological manipulation and potential therapeutic exploitation. Pharmacol Res 60: 77-84.
5. Pertwee RG, (2009) Emerging strategies for exploiting cannabinoid receptor agonists as medicines. Br J Pharmacol 156: 397-411.
6. Velasco G, Sanchez C, Guzman M, (2012) Towards the use of cannabinoids as antitumour agents. Nat Rev Cancer 12: 436-444.
7. Sarfaraz S, Adhami VM, Syed DN, Afaq F, Mukhtar H, (2008) Cannabinoids for cancer treatment: progress and promise. Cancer research 68: 339-342.
8. Carracedo A, Lorente M, Egia A, Blazquez C, Garcia S, et al. (2006) The stress-regulated protein p8 mediates cannabinoid-induced apoptosis of tumor cells. Cancer Cell 9: 301-312.
9. Galve-Roperh I, Sanchez C, Cortes ML, Gómez del Pulgar T, Izquierdo M, et al. (2000) Anti-tumoral action of cannabinoids: involvement of sustained ceramide accumulation and extracellular signal-regulated kinase activation. Nat Med 6: 313-319.
10. Salazar M, Carracedo A, Salanueva IJ, Hernandez-Tiedra S, Lorente M, et al. (2009) Cannabinoid action induces autophagy-mediated cell death through stimulation of ER stress in human glioma cells. The Journal of clinical investigation 119: 1359-1372.
11. Guzmán M (2005) Effects on cell viability. Handb Exp Pharmacol 627-642.
12. Izzo AA, Borrelli F, Capasso R, Di Marzo V, Mechoulam R, (2009) Non-psychotropic plant cannabinoids: new therapeutic opportunities from an ancient herb. Trends Pharmacol Sci 30: 515-527.
13. Ligresti A, Moriello AS, Starowicz K, Matias I, Pisanti S, et al. (2006) Antitumor Activity of Plant Cannabinoids with Emphasis on the Effect of Cannabidiol on Human Breast Carcinoma. J Pharmacol Exp Ther 318: 1375-1387.
14. Massi P, Vaccani A, Bianchessi S, Costa B, Macchi P, et al. (2006) The non-psychoactive cannabidiol triggers caspase activation and oxidative stress in human glioma cells. Cell Mol Life Sci 63: 2057-2066.
15. Massi P, Valenti M, Vaccani A, Gasperi V, Perletti G, et al. (2008) 5-Lipoxygenase and anandamide hydrolase (FAAH) mediate the antitumor activity of cannabidiol, a non-psychoactive cannabinoid. Journal of neurochemistry 104: 1091-1100.
16. McAllister SD, Christian RT, Horowitz MP, Garcia A, Desprez PY, (2007) Cannabidiol as a novel inhibitor of Id-1 gene expression in aggressive breast cancer cells. Molecular cancer therapeutics 6: 2921-2927.
17. McAllister SD, Murase R, Christian RT, Lau D, Zielinski AJ, et al. (2011) Pathways mediating the effects of cannabidiol on the reduction of breast cancer cell proliferation, invasion, and metastasis. Breast cancer research and treatment 129: 37-47.
18. Torres S, Lorente M, Rodriguez-Fornes F, Hernandez-Tiedra S, Salazar M, et al. (2011) A combined preclinical therapy of cannabinoids and temozolomide against glioma. Molecular cancer therapeutics 10: 90-103.
19. Marcu JP, Christian RT, Lau D, Zielinski AJ, Horowitz MP, et al. (2010) Cannabidiol enhances the inhibitory effects of delta9-tetrahydrocannabinol on human glioblastoma cell proliferation and survival. Molecular cancer therapeutics 9: 180-189.
20. Pacher P, Batkai S, Kunos G, (2006) The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol Rev 58: 389-462.
21. Garrett ER, Hunt A, (1974) Physicochemical properties, solubility, and protein binding of D9-Tetrahydrocannabinol. J Pharm Sci 63: 1056-1064.
22. Freiberg S, Zhu XX, (2004) Polymer microspheres for controlled drug release. Int J Pharm 282: 1-18.
23. Moses MA, Brem H, Langer R, (2003) Advancing the field of drug delivery: taking aim at cancer. Cancer Cell 4: 337-341.
24. Dubernet C, (2011) Targeting for drug delivery and imaging: an overview of the state of the art in cancer. Bull Cancer 98: 1363-1371.
25. Soma CE, Dubernet C, Barratt G, Benita S, Couvreur P, (2000) Investigation of the role of macrophages on the cytotoxicity of doxorubicin and doxorubicin-loaded nanoparticles on M5076 cells in vitro. J Control Release 68: 283-289.
26. Soma CE, Dubernet C, Bentolila D, Benita S, Couvreur P, (2000) Reversion of multidrug resistance by co-encapsulation of doxorubicin and cyclosporin A in polyalkylcyanoacrylate nanoparticles. Biomaterials 21: 1-7.
27. Lin R, Shi Ng L, Wang CH, (2005) In vitro study of anticancer drug doxorubicin in PLGA-based microparticles. Biomaterials 26: 4476-4485.
28. Gil-Alegre MEG-ÁI, Gutiérrez-Pauls L, Torres-Suárez AI, (2008) Three weeks release BCNU loaded hydrophilic-PLGA microspheres for interstitial chemotherapy: Development and activity against human glioblastoma cells. J Microencap 25: 561-568.
29. Sastre RL BM, Teijón C, Olmo R, Teijón JM, (2004) Preparation and Characterization of 5-Fluoruracil-Loaded Poly (ε-caprolactone) Microspheres for Drug Administration. Drug Dev Res 63: 41-53.
30. Hernan Perez de la Ossa D, Ligresti A, Gil-Alegre ME, Aberturas MR, Molpeceres J, et al. (2012) Poly-epsilon-caprolactone microspheres as a drug delivery system for cannabinoid administration: Development, characterization and in vitro evaluation of their antitumoral efficacy. J Control Release 161: 927-932.
31. Carracedo A, Gironella M, Lorente M, Garcia S, Guzman M, et al. (2006) Cannabinoids induce apoptosis of pancreatic tumor cells via endoplasmic reticulum stress-related genes. Cancer research 66: 6748-6755.
32. Vara D, Salazar M, Olea-Herrero N, Guzman M, Velasco G, et al. (2011) Anti-tumoral action of cannabinoids on hepatocellular carcinoma: role of AMPK-dependent activation of autophagy. Cell death and differentiation 18: 1099-1111.
33. Benny O, Menon LG, Ariel G, Goren E, Kim SK, et al. (2009) Local delivery of poly lactic-co-glycolic acid microspheres containing imatinib mesylate inhibits intracranial xenograft glioma growth. Clin Cancer Res 15: 1222-1231.
34. Benoit JP, Faisant N, Venier-Julienne MC, Menei P, (2000) Development of microspheres for neurological disorders: from basics to clinical applications. J Control Release 65: 285-296.
35. Menei P, Montero-Menei C, Venier MC, Benoit JP, (2005) Drug delivery into the brain using poly(lactide-co-glycolide) microspheres. Expert opinion on drug delivery 2: 363-376.
36. Nguyen TLU, Farrugia B, Davis TP, Barner-Kowollik C, Stenzel MH, (2007) Core-shell microspheres with surface grafted poly(vinyl alcohol) as drug carriers for the treatment of hepatocellular carcinoma. J Polym Sci 45: 3256-3272.
37. Ateh DD, Leinster VH, Lambert SR, Shah A, Khan A, et al. (2011) The intracellular uptake of CD95 modified paclitaxel-loaded poly(lactic-co-glycolic acid) microparticles. Biomaterials 32: 8538-8547.
38. Chakravarthi SS, Robinson DH, (2011) Enhanced cellular association of paclitaxel delivered in chitosan-PLGA particles. Int J Pharm 409: 111-120.
39. Hillegass JM, Blumen SR, Cheng K, MacPherson MB, Alexeeva V, et al. (2011) Increased efficacy of doxorubicin delivered in multifunctional microparticles for mesothelioma therapy. International journal of cancer 129: 233-244.
40. Kim I, Byeon HJ, Kim TH, Lee ES, Oh KT, et al. (2012) Doxorubicin-loaded highly porous large PLGA microparticles as a sustained- release inhalation system for the treatment of metastatic lung cancer. Biomaterials 33: 5574-5583.
41. Torelli-Souza RR, Cavalcante Bastos LA, Nunes HGL, Camara CA, Amorim RVS, (2012) Sustained release of an antitumoral drug from alginate-chitosan hydrogel beads and its potential use as colonic drug delivery Journal of Applied Polymer Science. 126: E409-E418.